ChromaDex Corporation (CDXC)
Market Cap | 194.89M |
Revenue (ttm) | 83.17M |
Net Income (ttm) | -3.53M |
Shares Out | 75.54M |
EPS (ttm) | -0.05 |
PE Ratio | n/a |
Forward PE | 505.88 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 232,484 |
Open | 2.680 |
Previous Close | 2.690 |
Day's Range | 2.550 - 2.710 |
52-Week Range | 1.250 - 4.650 |
Beta | 1.90 |
Analysts | Strong Buy |
Price Target | 6.00 (+132.56%) |
Earnings Date | Aug 7, 2024 |
About CDXC
ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufactur... [Read more]
Financial Performance
In 2023, ChromaDex's revenue was $83.57 million, an increase of 15.99% compared to the previous year's $72.05 million. Losses were -$4.94 million, -70.15% less than in 2022.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for CDXC stock is "Strong Buy." The 12-month stock price forecast is $6.0, which is an increase of 132.56% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/3/n/press11-2504871.jpg)
ChromaDex to Join Russell 2000® Index
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, today announc...
![](https://cdn.snapi.dev/images/v1/h/i/press15-2492695.jpg)
Milestone Phase II Clinical Study Demonstrates Niagen®, Patented Nicotinamide Riboside (NR), Improves Functional Mobility for Individuals with Peripheral Artery Disease (PAD)
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research, shares results from a milestone phase II cl...
![](https://cdn.snapi.dev/images/v1/l/4/press10-2477663.jpg)
ChromaDex to Launch Niagen+, the First-Of-Its-Kind Pharmaceutical-Grade Intravenous and Injectable Niagen® (Patented Nicotinamide Riboside Chloride or NRC)
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research and its application to healthy aging, unveil...
![](https://cdn.snapi.dev/images/v1/x/n/press17-2468138.jpg)
ChromaDex Receives Exclusive U.S. FDA Orphan Drug Designation (ODD) and Rare Pediatric (RPD) Disease Designation for Nicotinamide Riboside Chloride (NRC) for the Treatment of Ataxia Telangiectasia (AT)
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, today announced that the ...
![](https://cdn.snapi.dev/images/v1/t/n/press2-2461283.jpg)
ChromaDex to Participate in Renmark's Virtual Non-Deal Roadshow on Tuesday, June 11, 2024
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, announced today that it w...
![](https://cdn.snapi.dev/images/v1/s/t/conf2-2445379.jpg)
ChromaDex to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ: CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy-aging research, today announced that its...
![](https://cdn.snapi.dev/images/v1/u/n/press17-2443354.jpg)
ChromaDex's Niagen® Wins Prestigious NutraIngredients EU Healthy Ageing Ingredient of the Year Award
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, is proud to announce...
![](https://cdn.snapi.dev/images/v1/h/k/press9-2421694.jpg)
ChromaDex Corporation Reports First Quarter 2024 Financial Results
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the first quarter of 2024. First Quarter 2024 Financial and Recent Operational Hi...
![](https://cdn.snapi.dev/images/v1/e/m/press17-2399732.jpg)
ChromaDex's NIAGEN® (Patented Nicotinamide Riboside, NR), the Most Efficient and High-Quality NAD+ Precursor, Featured in New Solgar® Cellular Nutrition Cellular Energy Supplement
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, announces an ingredi...
![](https://cdn.snapi.dev/images/v1/o/e/press12-2391031.jpg)
ChromaDex Announces Nationwide Launch of Tru Niagen® at The Vitamin Shoppe®
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, announces that its f...
![](https://cdn.snapi.dev/images/v1/l/l/conf11-2387983.jpg)
ChromaDex to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, announced that it will ho...
![](https://cdn.snapi.dev/images/v1/z/i/press17-2385294.jpg)
ChromaDex Announces Inaugural Major Grocery Debut of Tru Niagen® at Sprouts Farmers Market
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, announces that its flagsh...
![](https://cdn.snapi.dev/images/v1/n/l/press18-2341723.jpg)
ChromaDex Announces Tru Niagen® is Now Third-Party Verified Through the Alkemist Assured™ Transparency Program
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, announces that its flagsh...
![](https://cdn.snapi.dev/images/v1/o/l/press12-2311846.jpg)
ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2023 Results
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC) today announced fourth quarter and fiscal year 2023 financial results. Fourth Quarter 2023 and Recent Highlights Total ...
![](https://cdn.snapi.dev/images/v1/p/t/conf13-2285865.jpg)
ChromaDex to Report Fourth Quarter 2023 Financial Results on Wednesday, March 6, 2024
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC) (“the Company”), a global bioscience company dedicated to healthy aging, announced that it will hold a conference call ...
![](https://cdn.snapi.dev/images/v1/x/0/press19-2259775.jpg)
ChromaDex to Participate in Renmark's Virtual Non-Deal Roadshow on Monday, February 12, 2024
LOS ANGELES--(BUSINESS WIRE)-- #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, announced today that it will be p...
![](https://cdn.snapi.dev/images/v1/2/v/conf5-2247305.jpg)
ChromaDex to Present at the Lytham Partners 2024 Investor Select Conference
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #IR--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, today announced that its Chief E...
![](https://cdn.snapi.dev/images/v1/u/q/press10-2203541.jpg)
ChromaDex Supports the US Military with its Industry Leading NAD+ Supplement, Tru Niagen®
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, is proud to announce its ...
![](https://cdn.snapi.dev/images/v1/a/u/press7-2193153.jpg)
Neurohacker Collective and ChromaDex Partner to Optimize Cellular Health with the Debut of Qualia NAD+
Qualia NAD+, Featuring ChromaDex's Patented Nicotinamide Riboside (NR) Ingredient, Niagen, Well Positioned To Become Category Leader In NAD+ Supplementation. SAN DIEGO , Dec. 12, 2023 /PRNewswire/ -- ...
![](https://cdn.snapi.dev/images/v1/a/5/press19-2177772.jpg)
A Milestone Phase I Randomized, Double-Blind Clinical Trial Demonstrates High-Dose Niagen®, Patented Nicotinamide Riboside (NR), Supplementation Induces a Potent NAD+ Response and Is Associated With Mild Improvement in Parkinson's Disease (PD)
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #NAD--ChromaDex Corp. (NASDAQ:CDXC), a global authority on Nicotinamide Adenine Dinucleotide (NAD+) and healthy aging research, shares results from a new breakth...
![](https://cdn.snapi.dev/images/v1/z/i/press10-2159221.jpg)
Newly Published Phase II Clinical Study Demonstrates that Supplementation with Niagen®, Patented Nicotinamide Riboside (NR), Elevates NAD+ Up to Fourfold, Improving Motor Coordination and Eye Movement in Ataxia Telangiectasia (AT) Patients
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC), one of the global authorities on Nicotinamide Adenine Dinucleotide (NAD+) and healthy aging research, shares results f...
![](https://cdn.snapi.dev/images/v1/h/8/press14-2149721.jpg)
ChromaDex to Participate in Renmark's Virtual Non-Deal Roadshow on Tuesday, November 14, 2023
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corporation (NASDAQ: CDXC), a global authority on Nicotinamide Adenine Dinucleotide (NAD+) and healthy aging research, announced today that...
![](https://cdn.snapi.dev/images/v1/9/b/press11-2147995.jpg)
ChromaDex Corporation Reports Third Quarter 2023 Financial Results
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ: CDXC) today announced financial results for the third quarter of 2023. Third Quarter 2023 and Recent Highlights Total net sa...
![](https://cdn.snapi.dev/images/v1/t/s/press2-2132847.jpg)
ChromaDex Debuts Clinical Strength Tru Niagen® Pro 1,000mg Featuring Niagen® (Patented Nicotinamide Riboside), One of the Most Efficient Nicotinamide Adenine Dinucleotide (NAD+) Boosters Available, to Consumers Nationwide
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC), a global authority on Nicotinamide Adenine Dinucleotide (NAD+) research and healthy aging, launches its clinical stren...
![](https://cdn.snapi.dev/images/v1/q/1/conf9-2130265.jpg)
ChromaDex to Report Third Quarter 2023 Financial Results on Wednesday, November 8, 2023
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #Bioscience--ChromaDex Corp. (NASDAQ:CDXC) (“the Company”) a global bioscience company dedicated to healthy aging, announced that it will hold a conference call ...